PM Q2 2026 Earnings Analysis
PM delivered strong H1 with 5.3% organic revenue growth and $4.16 adjusted EPS (+15.6%), driven by robust international smoke-free momentum and pricing power; FY guidance maintained.
Key Metrics
Wichtigste Erkenntnisse
- Strong H1: 5.3% organic revenue, 13.7% smoke-free growth, resilient combustible pricing.
- Q2 EPS $2.20 (+15%); accelerating U.S. ZYN investment with new variants and MRTP approval.
- FY guidance stable at 5-7% revenue, 7-9% OI growth, $8.26-$8.41 EPS, $13.5B cash flow.
Anhören auf
Verfügbar in
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Philip Morris International's second quarter 2026 results — and there's a lot going on here, including a CFO transition. But first, the standard stuff: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Right, and PMI gave us plenty to unpack. Let's start with the headline numbers, because they were strong.
Very strong. Organic net revenue growth of +8% for the quarter, operating income up +11%, and adjusted diluted EPS hit $2.20 — that's +14% currency-neutral, +15% in dollar terms. Quarterly net revenue crossed $11 billion for the first time ever.
And this wasn't just a currency tailwind story either. Outgoing CFO Emmanuel Babeau flagged that about a third of the EPS beat came from a favorable tax-related currency effect tied to the Russian ruble, but two-thirds was real operating strength — better SG&A phasing and a surprisingly strong combustible business.
Let's talk about that smoke-free business first, because it's really the engine of this whole story. IQOS adjusted in-market sales volume grew +5% in the quarter — that sounds almost modest until you realize it includes two known headwinds: an excise tax hike in Japan and a flavor ban in Poland.
Strip those out and IQOS growth was over 10% in Q2, north of 11% for the first half. That's the real underlying trend. IQOS also just cracked Kantar's list of top 100 most valuable global brands — pretty remarkable for a product that's only a decade old.
VEEV, their vapor brand, had an absolutely wild quarter — shipments up 55% in Q2, 72% for the half. Management says it's now the number one closed-pod brand in Europe and in global travel retail.
Now let's get into the U.S., because this is where investors have been the most impatient. ZYN shipments grew 2% year-over-year to 2.9 billion pouches, and importantly, that's despite lapping an inventory tailwind from last year. Sequentially versus a rough Q1, U.S. net revenue was up 38%, gross profit up 46%.
The bigger story is the product lineup. They just launched ZYN Ultra — a lower-priced moist variant meant to close the gap with competitors — and they're bringing 1.5 and 8 milligram dry formats in Q3. Babeau was pretty clear-eyed that it's early days, just two weeks of data on Ultra, but the initial read and consumer feedback were encouraging.
And there's a regulatory tailwind too — ZYN got Modified Risk Tobacco Product authorization on 20 SKUs, the only nicotine pouch product with that designation. That lets them actually market reduced-risk claims versus cigarettes, which is a real differentiator.
Here's the strategic pivot that stood out to me: management is choosing to step up U.S. investment hard in the second half — more marketing, a new brand campaign called "When It Clicks," expanded distribution — partly to build ZYN and partly to lay the groundwork for IQOS ILUMA's eventual U.S. launch, pending FDA action.
Which is why, despite beating estimates two quarters in a row, PMI held its full-year guidance rather than raising it. An analyst from Goldman actually pushed on this directly, and Babeau basically confirmed: yes, the flat guidance reflects the decision to plow incremental profit back into U.S. investment rather than let it drop straight to the bottom line.
Let's touch on combustibles too, because cigarettes had a surprisingly strong quarter — shipments up 1.1%, pricing up nearly 10%. Management was upfront that this outperformance was concentrated in markets like Turkey, Indonesia, Egypt, and India, where smoke-free alternatives are banned or barely present.
They actually improved their full-year cigarette volume outlook — now expecting a 2-3% decline instead of 3%. But they were careful to frame this as not-necessarily-repeatable, tied to specific market dynamics rather than a structural change.
Japan was the other hot topic in Q&A. IQOS there saw a Q2 dip after a big April excise-driven price increase, but management framed it as playing out exactly as expected — a "cultural shock" from the price jump, then recovery through the quarter. Category share held in the high 60s.
And there's a forward-looking angle that got some analyst attention — Japan is shifting to smaller, more predictable excise increases from 2027 through 2029, applied evenly across cigarettes and heated tobacco. Babeau suggested that's actually a friendlier setup for PMI going forward since, as the higher-priced brand, they're proportionally less impacted.
One more thing worth flagging for listeners — this was Emmanuel Babeau's final earnings call as Group CFO. He's handing the role to Massimo Andolina, currently PMI's European regional president, starting in August.
Andolina actually fielded a question himself on the call, about IQOS momentum in Europe post-flavor-bans, and sounded confident the underlying growth trend hasn't really changed once you strip out Poland and Hungary.
So, stepping back — what does this mean going forward? PMI reiterated full-year guidance: organic net revenue growth of 5-7%, operating income growth of 7-9%, and currency-neutral EPS growth of 7.5-9.5%. In dollar terms, with a currency tailwind now expected, that's an EPS range of $8.26 to $8.41.
The story here really is a company with more room to invest than it's choosing to spend right now — smoke-free is compounding nicely internationally, combustible is providing more cash cushion than expected, and they're using that flexibility to go all-in on the U.S. nicotine pouch opportunity. The key thing to watch next quarter is whether ZYN Ultra's early momentum holds up once the "first two weeks" honeymoon period from this call has more data behind it.
Definitely one to watch. Before we wrap up — everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
With a new CFO stepping in and a big U.S. investment push underway, PMI's next couple of quarters should be a real test of that strategy.
That's it for this episode of Beta Finch. Thanks for listening, and we'll catch you next time.